NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at three upcoming conferences.

Related Keywords

Washington ,United States ,Switzerland ,Nitai Kerem ,Shiran Zimri ,Ferenc Tracik ,Research Symposium ,International Symposium ,Drug Administration ,Linkedin ,Twitter ,Company Phase ,European Medicines Agency ,Society Of Neuroscience ,Neurosense Therapeutics Ltd ,Scientific Project Manager ,Biomarker Driven Approach ,Studying Amyotrophic Lateral Sclerosis ,Chief Medical Officer ,Orphan Drug Designation ,Sense Therapeutics ,Neurodegenerative Diseases ,Neurosense ,Clinical Efficacy ,Upcoming Conferences ,Ls ,